Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,295,757
  • Shares Outstanding, K 48,119
  • Annual Sales, $ 167,500 K
  • Annual Income, $ 52,230 K
  • EBIT $ -135 M
  • EBITDA $ -131 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 294.13
  • Price/Book 5.71

Options Overview Details

View History
  • Implied Volatility 141.44% (+8.45%)
  • Historical Volatility 62.64%
  • IV Percentile 96%
  • IV Rank 82.08%
  • IV High 156.91% on 09/18/25
  • IV Low 70.56% on 12/22/25
  • Expected Move (DTE 10) 0.85 (1.76%)
  • Put/Call Vol Ratio 0.83
  • Today's Volume 11
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 1,077
  • Open Int (30-Day) 716
  • Expected Range 47.52 to 49.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.73
  • Number of Estimates 7
  • High Estimate -0.67
  • Low Estimate -0.90
  • Prior Year -18.32
  • Growth Rate Est. (year over year) +96.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.00 +27.29%
on 01/14/26
49.25 -1.79%
on 02/05/26
+8.05 (+19.97%)
since 01/09/26
3-Month
30.00 +61.23%
on 11/13/25
49.25 -1.79%
on 02/05/26
+17.88 (+58.64%)
since 11/10/25
52-Week
6.71 +620.86%
on 04/09/25
49.25 -1.79%
on 02/05/26
+35.41 (+273.23%)
since 02/10/25

Most Recent Stories

More News
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 48.37 (+1.38%)
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 48.37 (+1.38%)
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate...

MAZE : 48.37 (+1.38%)
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 48.37 (+1.38%)
Maze Therapeutics to Participate in Four Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 48.37 (+1.38%)
Maze Therapeutics Appoints Hervé Hoppenot as Chairman

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

MAZE : 48.37 (+1.38%)
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 48.37 (+1.38%)
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), I-MAB (IMAB – Research Report) and Cidara Therapeutics...

IMAB : 4.63 (-0.22%)
CDTX : 221.38 (+0.03%)
MAZE : 48.37 (+1.38%)
Analysts’ Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), Repligen (RGEN – Research Report) and Monopar Therapeutics...

MNPR : 57.07 (-2.06%)
RGEN : 143.06 (-0.36%)
MAZE : 48.37 (+1.38%)
Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

VKTX : 28.75 (-1.88%)
MAZE : 48.37 (+1.38%)
IBRX : 6.56 (-5.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 52.81
2nd Resistance Point 50.66
1st Resistance Point 49.52
Last Price 48.37
1st Support Level 46.22
2nd Support Level 44.07
3rd Support Level 42.93

See More

52-Week High 49.25
Last Price 48.37
Fibonacci 61.8% 33.00
Fibonacci 50% 27.98
Fibonacci 38.2% 22.96
52-Week Low 6.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar